Medicis Pharmaceutical Corp. and Ipsen SA, which developed the experimental Reloxin product, are in talks with the Food and Drug Administration, Boulogne-Billancourt, France-based Ipsen said today in a statement. The injection relaxes the muscles that cause forehead lines using a type of botulinum toxin similar to the one in Allergan Inc.?s Botox. The delay should be a matter of weeks, according to brokerage Aurel BGC.”
This isn’t the first time Reloxin has gotten delayed; early last year, the FDA rejected Medicis’ initial application, citing a paperwork snafu.